Capsida Biotherapeutics’ Post

Be sure to share with users the great NIST search plugin you have for your GCMS solutions software! https://lnkd.in/gvZ67yDy This enables options in the NIST software such as: -Powerful deconvolution of complex GC/MS chromatograms -Searching up to 127 libraries in a combined search -e.g. , the combined library of NIST and Wiley (>1.1 million total spectra) can be searched in ~ 2 seconds -Assignment and use of extensive GC retention indices -Searching libraries for model compounds by similar and exact structure -Using MS Interpreter to explain EI fragmentation patterns for both user and commercial library spectra -Advanced hybrid EI search which greatly extends the standard EI search for unknown characterization

Read key results from the GATHER1 and GATHER2 clinical trials, conducted by IVERIC bio, Inc., An Astellas Company. This plain language summary publication shares easy to understand information about a potential treatment for geographic atrophy, an advanced form of dry age-related macular degeneration which can result in vision loss. Access the #PLSP here: https://lnkd.in/eQTBVHdC.

Stop by our exhibit booth at #AAPS #PharmSci360 and be sure to schedule a live demonstration of our new Predictor software in advance. Predictor features an advanced human fraction of dose absorbed (#Fa%) calculation model built upon the GUT framework by Kiyohiko Sugano. The model is designed to convert measured #flux profiles into Fa% profiles, using only the input flux data and basic physical #chemistry parameters obtainable from Rainbow fiber optic assays. https://lnkd.in/eMdkm3ZD

Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014   The CTA was submitted for a first in human Phase I study to primarily evaluate the safety and tolerability of CS014 in healthy volunteers. The design is a traditional single ascending and multiple ascending dose study for 1 week. Title of the study is “A first-in-human, open-label trial to investigate safety, tolerability, pharmacokinetics, and pharmacodynamics of CS014 in healthy volunteers after single and multiple administration”.   Read the full press release here:

Have you registered for our upcoming in-lab demo yet? There's only one week left to secure your spot for the second session of our DispenCell & CloneSelect Imager Virtual Demo with SEED Biosciences, happening on Thursday, November 30, at 11 am EST. Not only will you learn how the bundle verifies monoclonality, provides gentler dispensing of previous cells, decreases FTE hours and more, but you'll also have the exclusive opportunity to ask the experts your most pressing questions. Register using the link below 👇 #singlecell #biotechnology #biopharma #automation

RESISTANCE IS NOT AN OPTION

SPARTA offers novel insights into nanoformulations at the single particle level. Great to see the progress being made by SPARTA Biodiscovery! Feel free to reach out if you have any questions about the technology and becoming an early adopter #SPARTA #nanotechnology #nanoparticles #biopharmaceuticals

2024 is off to an exciting and interesting start in the world of TPD and small molecules. If you want a sneak peak at the summits coming up in 2024, please download the series brochure from the link below or message me to schedule a time to chat! #TPD #TargetedProteinDegradation #drugdiscovery #drugdevelopment #smallmolecule

I got 27th place/ 1946 and won a silver medal in a kaggle competition!!! This competition on Kaggle invited participants to forecast the efficacy of potential new medicines. This competition aimed to accelerate drug discovery by enabling more precise predictions of drug outcomes based on chemical data. For our solution, we prepared 2 models, one for which the structure of the molecule is shared in the training set, and another for molecules with unseen structures.  For the shared data, we enhanced accuracy by using a 1D CNN that treats SMILES as strings, incorporating residual connections and attention mechanisms. we used ChemBERTa, capable of transfer learning, and preserved generalization performance by freezing the first three layers during training to retain information from pre-trained molecules. This competition had a huge gap in molecular structure between the Public and Private leaderboards, making it a very "shaky" competition. Despite this, our team managed to create a highly robust model, achieved 8th on the Public and 27th on the private as well. Here is our solution. Any comments or questions are welcome! https://lnkd.in/gjhM5yBj

In the fast-paced field of pharmacogenomics, PGx laboratories often face the challenge of navigating tight deadlines, limited resources, and costly workflows. These issues not only slow down operations, but they can also be taxing on your laboratory professionals. 🤩 Discover an all-in-one solution that streamlines lab efficiency and transforms challenges into wins for PGx labs and their teams. 🤩 Dive into the everyday hurdles your PGx lab is up against in this infographic: https://hubs.li/Q0253sg90.   #AGBL #pgx #pharmacogenomics #moleculardiagnostics  #moleculartesting #molecularpathology